Optimizing iPSC-derived cell therapy development

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Optimizing iPSC-derived cell therapy development

With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and differentiation, and to optimize iPSC-derived cell therapy production workflows.

This webinar will help attendees to address a range of issues and bottlenecks in iPSC-derived cell therapy development. Using iPSC-derived CAR-NK (iNK) cells as an example, the panel will explore solutions for successful iPSC culturing and scale-up before sharing an optimized multi-step protocol to differentiate iPSCs to HSPCs to NK cells.

Attend this webinar to learn about:

Maintaining cell viability and function during iPSC culture expansion/scale-up
Addressing potential contamination risks and ensuring aseptic conditions
Selecting the optimal protocol from a range of complicated differentiation protocols
Controlling differentiation into specific cell types
Tackling regulatory, manufacturing, and logistical issues through use of fit-for-purpose solutions

Omar Farah

Manager, Field Applications at Thermo Fisher Scientific

Dr Farah received his doctorate from McGill University in Canada, where he studied early embryo lineage specification and development of the female reproductive tract needed for proper embryo-uterine crosstalk. Omar continued his postdoctoral work at the University of California, San Diego, where he focused on using stem cell-based models to study extra-embryonic lineage specification, trophoblast differentiation, and placental development. Currently, Dr Farah is working at Thermo Fisher, managing a team of regenerative medicine field application scientists supporting stem cell, neurobiology, cell and gene therapy workflows.

Mark Kennedy

Staff Scientist at Thermo Fisher Scientific

Abigail Becker

Staff Scientist at Thermo Fisher Scientific

Michael Akenhead

Staff Scientist at Thermo Fisher Scientific

Carl Dargitz

Senior R&D Manager, Cell & Gene Therapy Platforms at Thermo Fisher Scientific

Carl Dargitz is a Senior Manager in the Cell & Gene Therapy Platforms R&D group developing cell therapy instrumentation at Thermo Fisher Scientific. His team lead the development of the CTS Rotea Counterflow Centrifugation System. Previously, he developed reprogramming and characterization assays for PSCs and immune cells at Thermo Fisher. Before joining Thermo Fisher, he worked at the Salk Institute for Biological Studies at the stem cell core facility managing the core’s reprogramming and characterization services. He received his M.S. from California Polytechnic State University, San Luis Obispo in Biomedical Engineering with a specialization in stem cell research in 2013.